Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca: Saxagliptin reduces glucose control measures with metformin

AstraZeneca: Saxagliptin reduces glucose control measures with metformin

12th September 2008

AstraZeneca has presented new data for its investigational diabetes medication saxagliptin for the first time at the annual meeting of the European Association for the Study of Diabetes.

The company revealed the results of a 24-week phase III clinical study that showed saxagliptin combined with metformin as an initial therapy resulted in reductions of all key glucose control measures studied.

Treatment-naive patients experienced a reduced measure of post-prandial glucose, fasting plasma glucose and glycosylated hemoglobin level.

Saxagliptin is an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 enzyme and is being developed by the company in conjunction with Bristol-Myers Squibb.

Professor Anthony Barnett, University of Birmingham and Heart of England NHS Foundation Trust, said: “With these new data, phase III studies for saxagliptin have demonstrated that saxagliptin improved key markers for glucose control when given with standard therapies for type 2 diabetes and as a monotherapy.”

He added the clinical trial programme for the drug evaluated over 5,000 patients, 4,000 of who were administered with saxagliptin.

In January 2007, AstraZeneca and Bristol-Myers Squibb announced a partnership agreement for the development and marketing of two compounds being assessed as treatments for type 2 diabetes.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.